ENZNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 02:33):

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron...

Stats
本日の出来高	900.00
平均出来高	17 201.00
時価総額	6.19M
EPS	$0 ( 2024-02-09 )
次の収益日	( $0 ) 2024-05-06
Last Dividend	$0.120 ( 2019-09-30 )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-16	Read Randolph C	Buy	84 550	Common Stock
2023-06-14	Read Randolph C	Buy	15 000	Common Stock
2022-06-09	Firestone Jaffrey Adam	Buy	0
2021-08-13	Couchman Jonathan	Sell	57 500	Common Stock, $0.01 par value
2021-08-13	Couchman Jonathan	Sell	50 000	Common Stock, $0.01 par value

INSIDER POWER
100.00
Last 86 transactions
Buy: 34 996 838 \| Sell: 942 903

Enzon Pharmaceuticals, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Enzon Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0.0185

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0.0185

FY	2022
収益:	$26 000.00
総利益:	$26 000.00 (100.00 %)
EPS:	$-0.00250

FY	2021
収益:	$701 000
総利益:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Enzon Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Enzon Pharmaceuticals, Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$2.00	2012-12-06
Last Dividend	$0.120	2019-09-30
Next Dividend	$0	N/A
Payout Date	2019-10-15
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$5.38	--
Avg. Dividend % Per Year	0.00%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-24)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for PNK

Symbol	Title	Last dividend	Frequency	Yearly Dividend
CNLHN	Ex Dividend Knight	2023-08-09	Quarterly	0.00%
UEPEP	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
RSRV	Ex Dividend Junior	2023-06-06	Annually	0.00%
PFBX	Ex Dividend Knight	2023-05-01	Annually	0.00%
FREVS	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
EFSI	Ex Dividend Knight	2023-08-04	Quarterly	0.00%
TBTC	Ex Dividend Junior	2023-08-31	Sporadic	0.00%
BVHBB	Ex Dividend Junior	2023-09-01	Semi-Annually	0.00%
QNBC	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
JUVF	Ex Dividend Knight	2023-08-16	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	0.0288	1.200	9.04	10.00	[0 - 0.3]
returnOnEquityTTM	0.0390	1.500	-0.678	-1.017	[0.1 - 1]
payoutRatioTTM	0.929	-1.000	0.714	-0.714	[0 - 1]
currentRatioTTM	27.62	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	27.43	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	27.43	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.51	1.000	9.65	0	[1 - 100]
returnOnEquityTTM	0.0390	2.50	-0.436	-1.017	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0176	2.00	9.99	10.00	[0 - 30]
payoutRatioTTM	0.929	1.500	0.714	-0.714	[0 - 1]
pegRatioTTM	-0.183	1.500	-4.55	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				2.03

Enzon Pharmaceuticals,

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.